The Scott Baker Story -part 2 (DRAFT ONLY, DO NOT PUBLISH)

 INSIGHTS FROM A CANCER SURVIVOR-ADVOCATE

Lessons in Movement, Purpose, and Paying It Forward

From an exclusive interview with SCOTT BAKER / 4x Cancer Survivor

Edited by: Lennard M. Goetze, Ed.D   |  Daniel Root

 

"...that moment with Jason meant more to me than I expected. It reminded me how powerful human connection can be in the middle of illness."

Cancer has a way of changing everything. It changes how you look at time, at your body, at the people around you, and at the meaning of being alive. When I was first diagnosed at 29, I didn’t realize that cancer would shape the rest of my life—not just medically, but personally and spiritually.

 

Over the years, I’ve faced cancer four separate times, including a battle with brain lymphoma. But what those experiences gave me was a perspective I never expected: a responsibility to help others navigate the road I’ve already walked. My mission now isn’t just surviving—it’s helping other people survive too.

 

Through advocacy, speaking engagements, patient visits, and simple conversations, I try to share what I’ve learned from living through cancer treatment and recovery. Survivorship isn’t just about making it through therapy—it’s about learning how to live again with purpose, resilience, and compassion.

---

 

Movement as Medicine: My Journey with Exercise Oncology

One of the most important lessons I’ve learned through cancer is that movement matters. I had never even heard the term exercise oncology until recently, but the truth is I’ve been living it for decades. “I have never heard the term exercise oncology,” I’ve said before, “but I’ve been living it for 27 years.”  When I was first diagnosed, all I could think about was getting back to the gym. For me, the gym represented healing. It represented normal life. And as I went through treatment after treatment, that belief stayed with me. If all I could do was walk, then I walked. And I walked a lot.

 

Sometimes that meant a long walk around the neighborhood. Other days it meant just making it to the mailbox. But movement—any movement—meant progress.

 

Chemotherapy and cancer treatment take a serious toll on the body. The drugs attack fast-growing cells, which means they affect far more than the cancer itself. I lost my sense of taste. My digestive system was wrecked. I experienced brain fog—what many patients call “chemo brain.” And the exhaustion is hard to explain to someone who hasn’t lived through it. It’s not just being tired—it’s a deep physical depletion.

But I learned something important: even small movement helps the body fight back.

 

Exercise helps circulation. It helps the body process medications. It helps clear toxins from the system. And maybe most importantly, it gives you back a sense of control.

 

There are many things cancer patients can’t control. We can’t control the cells in our bodies that start behaving badly. But there are things we can control. We can control how we move. We can control how we manage stress. And we can control the food we put into our bodies.

 

For me, those became the three pillars of survival. Today I still participate in the Livestrong program at the YMCA, working out alongside other cancer survivors in 12-week training groups. I’ve been doing it for more than a decade now. Every time I walk into that room, I’m reminded that movement is one of the most powerful tools we have in the fight against cancer.

 

---

The Hidden Cost of Cancer Treatment

Cancer treatment saves lives, but it doesn’t come without a price. Chemotherapy is incredibly powerful medicine. It can wipe out cancer cells and give people a second chance at life. But it also puts enormous stress on the body.

 

Patients lose strength. They lose stamina. Many struggle with neurological effects like brain fog and difficulty concentrating. The fatigue can feel overwhelming. That’s why movement is so important—even when it feels impossible. I always encourage patients to start small.

 

Some days your victory may simply be standing up and walking down the hallway. Other days it might be a three-mile walk. The key is not comparing one day to another. If you move, you’re winning.

---

 

NO ONE RISES ALONE What Almost Dying Taught Me About Living- By Scott Baker I have battled cancer four times including two bouts with a rare form of brain cancer. The moment I learned that I had a brain tumor I wasn’t comfortable with who I was as a human being. I decided that the experience of battling brain cancer would help me find a path to being comfortable with myself. I had faith in that idea but I had no idea how brain cancer would provide the clarity I needed. As I wrote the stories that make up this book I began to understand that it was the experiences I had with perfect strangers that changed me. The events that took place in the extremely difficult 12 months that followed proved to be the perfect people at the perfect time over and over and the sum of all those experiences provided me with an inner peace I never knew could exist. When I finally finished active treatment and was discharged from the hospital I needed to share the experiences I had that carried me through the most difficult time of my life and changed my life at the same time. The same thing is available to all of us. All we need to do is choose to see it.  ORDER YOUR COPY TODAY Copyright © 2025

Paying It Forward

One of the most meaningful parts of survivorship for me has been learning the importance of paying it forward. When I underwent a stem cell transplant for brain lymphoma, I was placed in isolation for weeks. It was one of the most difficult periods of my life.

 

Then something unexpected happened. A woman named Rosalie came into my hospital room. She had the exact same disease I had, and she had gone through the exact same transplant two years earlier. Seeing her that day completely changed how I looked at the next month of treatment. Suddenly I wasn’t just facing the unknown—I was seeing proof that someone else had survived it. That visit gave me hope.

 

Years later, I had the chance to do the same thing for another patient named Jason who was undergoing the same transplant. I went to Sloan Kettering to sit with him for about an hour, just to talk and share my experience. To me, paying it forward means giving someone something that someone once gave you when you needed it most.  That moment with Jason meant more to me than I expected. It reminded me how powerful human connection can be in the middle of illness.

---

 

The Role of Advocacy

Cancer advocacy often starts with a simple idea: be useful to someone else. During my treatments, the nurses who cared for me became some of my greatest inspirations. They didn’t just administer medication or monitor vital signs. They treated me like family. They treated me like their own son.

 

That level of compassion stuck with me. I realized I might not be able to wear scrubs or a white coat, but there had to be another way I could help people.

 

Over the years I’ve found many ways to do that. I visit patients in hospitals. I speak to students and community groups. I participate in donor-registry drives encouraging people to become stem-cell donors. I share my story wherever it might help someone who is struggling.

 

Advocacy doesn’t always require a formal title. Sometimes it simply means showing up for someone who needs encouragement. And when you do that, something interesting happens—you receive something back. Helping someone else reminds you that your own struggle had purpose.

---

 

Outreach, Storytelling, and Social Media

In today’s world, outreach also happens online. Social media has become an incredibly powerful tool for cancer advocacy. A single post can reach thousands of patients, survivors, physicians, and caregivers around the world. That reach matters. Sharing stories online creates connections. It helps survivors find each other. It helps newly diagnosed patients realize they’re not alone. For advocates like me, the goal isn’t fame or attention. It’s visibility for hope. The more stories we share, the more people realize that survivorship is possible.

 

Living with Purpose

Today my life looks very different than it did before cancer. I spend time speaking at colleges, encouraging young people to join stem-cell donor registries. I continue my exercise programs with other survivors. And I try to make myself available whenever someone needs encouragement.

 

If cancer taught me anything, it’s that survival carries responsibility. When you make it through something that difficult, you have knowledge others don’t yet have. And that knowledge can become a lifeline for someone else. That’s why I keep telling my story.

 

Because somewhere out there is a patient sitting in a hospital room, wondering if they’ll make it.

And if hearing my story helps them believe they can—then everything I went through has meaning.

 

Spotlight: Dr. Jay Harness of CancerFitness.org

The Surgeon Who Refused to Let Healing End in the Operating Room

A Visionary Champion of Exercise Oncology, Patient Empowerment, and Survivorship Care

By: Lennard M. Goetze, Ed.D - Sr. Publisher of  the AngioMedical Press and ICRS NEWS (Integrative Cancer Resource Society)

For nearly five decades, Dr. Jay Harness built his life around the operating room. As a surgical oncologist specializing in breast cancer, he helped guide thousands of patients through one of the most frightening moments of their lives. He removed tumors, navigated complex treatment pathways, and bore witness to both triumph and loss. But after 47 years of clinical practice, Dr. Harness reached a profound realization: surgery and medicine alone were not enough to fully serve the long-term needs of people living with and beyond cancer.

Instead of stepping quietly into retirement, Dr. Harness pivoted into what would become the most unexpected—and arguably most impactful—chapter of his career: Exercise Oncology. “I was thunderstruck by the science,” Dr. Harness says. “For over 35 years, there were thousands of clinical trials and tens of thousands of publications showing how exercise improves survival, reduces recurrence, and helps patients tolerate treatment. And yet, most physicians had never been taught this.”

This moment of discovery became a call to action. Dr. Harness realized that a powerful body of evidence existed—but it was trapped inside academic silos. Researchers in exercise physiology, kinesiology and sports medicine had been building a mountain of data, while oncologists and surgeons largely remained unaware of its implications. The result? Patients were missing out on one of the most accessible, evidence-backed tools available to support recovery, resilience, and long-term survival.

“For decades, the scientists were essentially talking to themselves,” he explains. “There was very little crossover into everyday oncology care. That gap is what I’m trying to fill.”

From Scalpel to Systems Change

Dr. Harness’s career shift was not about abandoning medicine—it was about expanding it. He recognized that true healing does not end when a tumor is removed or chemotherapy concludes. Cancer changes the body, the mind, and the identity of a person. Survivorship is not simply about being alive—it is about restoring function, confidence, and quality of life.

Through his leadership in CancerFitness.org, Dr. Harness has created an educational hub designed for both patients and clinicians. The platform translates complex science into practical guidance on how movement can support patients before treatment (prehabilitation), during therapy, and throughout long-term survivorship. “Exercise oncology should be a continuum of care,” he says. “It’s not just something you do after treatment. It starts before diagnosis, continues during therapy, and becomes part of long-term survivorship.”

The science supports him. Patients who were physically active prior to diagnosis show improved survival outcomes. Those who engage in moderate exercise during treatment often tolerate chemotherapy better and report less fatigue, anxiety, and depression. Long-term survivors who remain active experience significantly lower all-cause mortality.

“This isn’t about running marathons,” Dr. Harness emphasizes. “We’re talking about moderate activity—brisk walking, cycling, resistance training. Small, consistent movement can change biology.”

The Biology of Movement

What excites Dr. Harness most is not only what exercise does—but how it does it. “Every time muscles contract, they release signaling molecules that reduce inflammation and influence cancer-related pathways,” he explains. “Exercise stimulates mitochondrial function, improves immune response, enhances blood flow, and supports neurological health.”

This emerging understanding of exercise as a biological intervention reframes movement as more than lifestyle advice—it becomes a clinical tool. In this view, walking is not simply “good for you”; it is a molecular signal that tells the body how to heal. “We’re finally starting to understand that movement is medicine at the cellular level,” he says. “That changes how we should think about recovery.”

Education: The Missing Link in Cancer Care

Despite overwhelming evidence, adoption remains slow. Dr. Harness identifies physician education as the single greatest barrier. “The vast majority of my colleagues were never taught this science in medical school or residency,” he says. “You can’t refer patients to something you don’t know exists.”

To change this, Dr. Harness lectures nationally and internationally, including at major breast surgery and oncology conferences. He works to normalize exercise oncology as part of standard supportive care—not as an optional add-on, but as a core component of treatment strategy. “If Australia can integrate exercise into standard cancer care, we can too,” he notes. “This is not radical. It’s rational.”

Building Infrastructure for Survivors

Through collaborations with organizations like Maple Tree Cancer Alliance, Dr. Harness advocates for certified exercise oncology specialists embedded within cancer centers and community fitness programs. His goal is not to tell patients to “exercise more,” but to create structured, supervised pathways that safely integrate movement into care plans.

“Brochure therapy doesn’t work,” he says bluntly. “Handing patients a pamphlet and hoping they figure it out is not healthcare. Referrals to structured programs work.” This approach reflects Dr. Harness’s systems-level thinking: education alone is not enough. Infrastructure matters. Access matters. Training matters.

A Vision for 2026 and Beyond

With the formation of the Cancer Fitness Foundation, Dr. Harness is laying the groundwork for broader adoption of exercise oncology worldwide. His vision for the coming years includes expanding clinician education, increasing research collaborations, and embedding exercise programs within standard oncology workflows. “My goal is simple,” he says. “Exercise oncology should no longer be considered ‘alternative.’ It should be expected.”

At its heart, Dr. Harness’s work is not about fitness—it is about dignity. It is about restoring agency to patients who often feel their bodies have betrayed them. It is about reminding people that movement is not a punishment or a chore—it is a form of biological hope.

“Cancer takes a lot away from people,” he reflects. “Exercise gives them something back—a sense of control, strength, and forward momentum.”

The Legacy of a Modern Healer

Dr. Jay Harness represents a new archetype in oncology: the surgeon who refuses to let care stop at the operating table, the educator who bridges science and humanity, and the visionary who understands that healing is not only about removing disease—but restoring life. “If we truly care about outcomes,” he says, “we have to care about how people live after treatment. Survival is the starting line, not the finish.” In a healthcare system still catching up to the science of survivorship, Dr. Harness stands as both a catalyst and a compass—pointing toward a future where movement is no longer an afterthought, but a cornerstone of cancer care.

 

 

 

 

PART 2

Active Surveillance After Cancer: Restoring the Terrain — Imaging the Body Back to Strength

By Dr. Robert L. Bard, MD,DABR, FAIUM, FASLMS
(Cancer Radiologist | Post-Treatment Active Surveillance Specialist)

As a cancer radiologist, much of my work takes place after the most visible battles are over. I see patients in the phase of active surveillance—the long, watchful period following surgery, chemotherapy, radiation, or immunotherapy. This is the quiet chapter of cancer care that rarely makes headlines. Tumors may be gone or shrinking, scans may show stability, and lab values may look reassuring. Yet the body I image is often profoundly altered by the treatments that saved the patient’s life.

What I monitor through ultrasound, Doppler imaging, elastography, thermography, and optical vascular scanning is not just the absence of disease—but the condition of the terrain in which healing must continue. Fibrosis, vascular compromise, lymphatic congestion, mitochondrial fatigue, neuropathy, and inflammatory burden often persist long after treatment ends. In many patients, the question is no longer “Is the cancer visible?” but rather, “Is the body resilient enough to prevent its return?”

This is where restorative medicine, rehabilitation, and exercise oncology intersect with diagnostic imaging.

From my clinical vantage point, movement is not a lifestyle suggestion—it is a biological signal. The tissues I evaluate change when circulation improves. Microvascular flow shifts. Oxygenation patterns normalize. Fibrotic tissue softens. Neural conductivity responds. These are measurable phenomena. When patients engage in consistent, moderate physical activity as part of their recovery, I often observe functional improvements in tissue health that imaging can corroborate over time.

Beyond the physical domain, there is a deeper, often underestimated dimension to survivorship: spirit and emotional resilience. I have witnessed how depression, chronic stress, and emotional withdrawal manifest physiologically. There is now strong scientific support for what clinicians have long suspected: psychological distress directly impairs immune function. Elevated cortisol from chronic stress suppresses natural killer cell activity—one of the immune system’s frontline defenses in tumor surveillance. Inflammation increases. The hypothalamic-pituitary-adrenal (HPA) axis becomes dysregulated. The body shifts into a biological state that is less equipped to heal and less capable of defense.

In this context, exercise becomes more than physical rehabilitation. It becomes an immune-supportive intervention. Movement lowers baseline cortisol over time, improves mood through neurochemical regulation, and enhances mitochondrial function. These changes translate into improved immune signaling, better treatment tolerance, and, critically, improved psychological stamina. Patients who move tend to endure treatment better—not just physically, but emotionally. And emotional endurance matters. Hope, agency, and participation in one’s own recovery are not abstract ideals; they are biological contributors to immune competence.

From the imaging perspective, active surveillance is not passive observation. It is an opportunity to track recovery. Safe, repeatable imaging allows us to assess vascular response, tissue remodeling, inflammatory patterns, and structural recovery over time. When movement is integrated into survivorship care, we can correlate functional change with imaging evidence—providing patients with visual proof that their efforts are reshaping their internal environment.

Cancer treatment is often described as a war. But recovery is closer to reconstruction. It requires restoring circulation, rebuilding metabolic resilience, calming inflammation, and re-establishing neurological balance. Exercise oncology, when guided responsibly, supports each of these domains. Imaging allows us to verify that restoration is occurring—not as theory, but as measurable change within the body.

Active surveillance should not only watch for recurrence. It should actively support recovery. When diagnostics, movement, and emotional resilience align, the body is no longer merely surviving cancer—it is reclaiming its capacity to defend itself.

In this emerging model of post-cancer care, we are no longer just looking for what remains of disease. We are imaging the return of strength.

CANCER TREATMENTS, MICROCIRCULATION AND THE FEET

How oncology therapies reshape peripheral circulation, nerve health, and tissue integrity—and why the feet serve as a diagnostic sentinel

By: Lennard M. Goetze, Ed.D  / Phil Hoekstra, Ph.D

 

Introduction

Modern cancer therapies have transformed survival outcomes, yet survivorship often carries a hidden burden: long-term compromise of peripheral circulation, nerve integrity, and tissue resilience—most visibly expressed in the feet. Chemotherapy disrupts microvascular networks and damages peripheral nerves; radiation alters vascular regulation and autonomic signaling; and targeted and immunotherapies introduce new patterns of inflammatory and ischemic stress. These physiologic disruptions commonly manifest in the lower extremities as numbness, burning pain, edema, color changes, delayed wound healing, nail pathology, and skin breakdown—symptoms that erode mobility, independence, and quality of life.

PodiatryScan reframes the feet as a sentinel region for treatment-related injury—where early shifts in perfusion, nerve function, and tissue tolerance can be detected, monitored, and managed longitudinally. Rather than waiting for survivorship complications to escalate into disability, a proactive surveillance model identifies emerging microcirculatory compromise and neuropathic stress earlier in recovery. Positioned within oncology survivorship care, PodiatryScan supports preventive foot monitoring, rehabilitation planning, protective strategies, and timely referral—elevating post-cancer care from reactive management to function-preserving, anticipatory medicine.

---

 

1) Chemotherapy-Induced Peripheral Neuropathy (CIPN) and the Feet

CIPN is among the most prevalent and functionally limiting toxicities of cancer therapy. Agents such as taxanes, platinum compounds, vinca alkaloids, and proteasome inhibitors damage sensory axons and small fibers that innervate the feet, producing numbness, paresthesia, burning pain, and proprioceptive loss. The feet—being distal—are affected earliest and often most severely. Sensory loss increases fall risk, impairs balance, and predisposes to unnoticed trauma. Persistent neuropathy can outlast treatment by years, reshaping gait mechanics and loading patterns across the foot and ankle. Surveillance that tracks sensory thresholds, skin integrity, and functional stability helps clinicians intervene with protective footwear, balance training, and timely referrals to neurology or rehab before secondary injuries accrue.

 

2) Microvascular Injury and Ischemic Stress

Many cytotoxic agents injure endothelial cells and disrupt nitric-oxide–mediated vasodilation, diminishing capillary perfusion in distal tissues. Reduced microcirculation compromises oxygen delivery to the toes and plantar skin, delaying healing after minor cuts or pressure points. In patients with pre-existing vascular disease, diabetes, or smoking history, treatment-related microangiopathy compounds ischemic risk. The feet, as terminal vascular territories, often reveal early signs of perfusion stress—color changes, temperature asymmetry, and delayed capillary refill—making them an ideal surveillance target for circulatory compromise during survivorship.

 

3) Radiation Effects on Vascular Regulation and Autonomic Control

Radiation therapy can induce long-lasting endothelial injury, fibrosis, and autonomic dysregulation within treated fields and along neurovascular pathways. Although the feet are rarely irradiated directly, autonomic disturbances and systemic inflammatory responses can alter distal vascular tone and sweat gland function. Patients may report cold intolerance, color changes, edema, or brittle skin and nails in the lower extremities. These changes increase susceptibility to fissures, infection, and pressure injury—particularly in older adults or those with limited mobility. Monitoring distal tissue resilience becomes part of comprehensive survivorship care.

 

4) Hand–Foot Syndrome (Palmar-Plantar Erythrodysesthesia)

Certain chemotherapies and targeted agents precipitate hand–foot syndrome, characterized by erythema, pain, swelling, desquamation, and blistering on palms and soles. Plantar involvement threatens ambulation and adherence to therapy. Early identification of plantar skin stress enables dose adjustments, topical protection, and offloading strategies that preserve function and reduce treatment interruptions.

 

5) Lymphedema, Edema, and Tissue Vulnerability

Cancer-related lymphatic injury—whether from surgery, radiation, or systemic inflammation—can manifest as lower-extremity edema. Chronic swelling increases skin tension, reduces microcirculatory exchange, and raises infection risk. The feet, constrained by footwear and dependent positioning, are particularly vulnerable to maceration and fissuring. Longitudinal surveillance guides compression strategies, footwear modification, skin care, and referral to lymphedema therapy to prevent recurrent cellulitis and mobility decline.

 

6) Immunotherapy and Inflammatory Dermatoses

Checkpoint inhibitors and other immunotherapies introduce novel inflammatory toxicities affecting skin and small vessels. Acral dermatitis, vasculitic changes, and microvascular inflammation may present on the feet as painful erythema, purpura, or ulceration. Differentiating immune-mediated dermatoses from ischemic or infectious etiologies is critical to avoid mismanagement and unnecessary treatment interruptions. Structured foot surveillance supports earlier triage and targeted management.

 

7) Nail and Skin Barrier Disruption

Onycholysis, brittle nails, paronychia, xerosis, and fissuring are common during systemic therapy. On the feet, nail dystrophy alters pressure distribution in footwear, while skin barrier breakdown invites fungal and bacterial infection. Preventive foot care—routine inspection, nail management, moisturization, and footwear assessment—reduces secondary complications that disproportionately burden survivors with neuropathy or edema.

 

8) Musculoskeletal Deconditioning and Gait Changes

Pain, fatigue, and neuropathy alter loading patterns across the forefoot and heel, precipitating callus formation, plantar fasciopathy, and stress reactions. Deconditioning compounds these biomechanical shifts, increasing fall risk. Integrating podiatric assessment with rehabilitation planning preserves mobility and helps survivors return to activity safely.

 

9) Infection Risk in an Immunocompromised Host

Neutropenia and mucocutaneous barrier injury elevate the risk of tinea pedis, cellulitis, and wound infection in the feet. Minor interdigital fissures can escalate rapidly in immunocompromised patients. Proactive surveillance, patient education on daily foot checks, and rapid response pathways for early infection signs are essential.

 

10) Why the Feet Are a Sentinel in Survivorship

The feet concentrate the downstream effects of vascular, neurologic, inflammatory, and mechanical stressors introduced by cancer therapies. Because they are distal, load-bearing, and richly innervated, early dysfunction becomes clinically apparent there first. PodiatryScan operationalizes this insight through structured, longitudinal foot monitoring—integrating perfusion cues, sensory status, skin integrity, and functional mobility into survivorship workflows. The result is earlier detection, smarter referrals, targeted protection, and function-preserving care that keeps survivors mobile and independent.

 

---

Clinical Takeaways

·        Screen early and often for sensory loss, perfusion stress, and skin barrier compromise in the feet during and after therapy.

·        Act preventively with footwear optimization, offloading, skin care, balance training, and timely specialty referral.

·        Coordinate care across oncology, podiatry, neurology, rehab, and wound services to prevent small problems from becoming disabling sequelae.

---

References

1.       American Cancer Society. (2023). Hand–foot syndrome (palmar-plantar erythrodysesthesia).

2.       Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012). Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Critical Reviews in Oncology/Hematology, 82(1), 51–77.

3.       Cavaletti, G., & Marmiroli, P. (2010). Chemotherapy-induced peripheral neurotoxicity. Nature Reviews Neurology, 6(12), 657–666.

4.       Hershman, D. L., et al. (2014). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers. Journal of Clinical Oncology, 32(18), 1941–1967.

5.       Lacouture, M. E., et al. (2011). Clinical practice guidelines for the prevention and treatment of EGFR inhibitor–associated dermatologic toxicities. Supportive Care in Cancer, 19(8), 1079–1095.

6.       National Cancer Institute. (2024). Peripheral neuropathy (PDQ®)–Health professional version.

7.       Rockson, S. G. (2018). Lymphedema. American Journal of Medicine, 131(3), 276–280.

8.       Siegel, R. L., Miller, K. D., & Jemal, A. (2024). Cancer statistics. CA: A Cancer Journal for Clinicians, 74(1), 17–48.

9.       Smith, E. M. L., et al. (2013). The reliability and validity of a modified Total Neuropathy Score in patients with CIPN. Journal of the Peripheral Nervous System, 18(1), 45–51.

10.     Sonis, S. T. (2013). Pathobiology of mucositis. Nature Reviews Cancer, 4(4), 277–284.

Beyond Suppression: Rethinking Prostate Cancer Through Biology, Balance, and Precision

 Chapter 7 of ProstateScan 2026:

REFRAMING PROSTATE CANCER THROUGH EVIDENCE, QUALITY OF LIFE, AND PRECISION-GUIDED CARE

Insights from Dr. Alex Van Hoof

For decades, prostate cancer has been defined—and treated—through the lens of hormonal suppression. Yet as research advances and clinical experience deepens, a more nuanced picture is emerging—one that balances tumor biology, patient quality of life, and precision-guided innovation. According to Dr. Alex Van Hoof, a clinician deeply engaged in prostate cancer research and education, the field is undergoing a quiet but meaningful transformation

Dr. Van Hoof points to the historical foundations of prostate cancer care, dating back to the landmark discoveries of Huggins and Hodges in the 1940s, which established androgen deprivation as a powerful means of controlling disease progression. That principle remains valid today—but its application has grown more sophisticated. Modern care now recognizes that while androgen signaling drives progression in established cancer, prostate cancer itself is initiated by genetic and molecular changes long before hormones become dominant players.

One of the most significant recent shifts, Dr. Van Hoof notes, is the growing use of intensified combination therapy in men diagnosed with high-risk disease. Large trials such as STAMPEDE have demonstrated that adding advanced androgen receptor pathway inhibitors (ARPIs) to traditional androgen deprivation therapy and radiation can substantially improve overall survival and metastasis-free survival. What was once applied to a minority of patients is rapidly becoming standard practice for a majority, reflecting a recalibration of how aggressively clinicians intervene earlier in the disease course.

Yet progress is not limited to escalation. Dr. Van Hoof emphasizes that innovation in prostate cancer also involves re-examining long-held assumptions, particularly around hormones themselves. One of the most provocative areas of ongoing research involves testosterone replacement therapy (TRT) in select men who have undergone definitive treatment for localized prostate cancer. Historically viewed as contraindicated, TRT is now being studied as a potential quality-of-life intervention in carefully selected patients.

This evolving conversation has been championed by Dr. Abraham (Abe) Morgentaler, a urologist and researcher whose work has challenged the dogma that any testosterone exposure is inherently dangerous in men with a history of prostate cancer. Dr. Morgentaler’s research has helped clarify the concept of a saturation model, suggesting that once androgen receptors are maximally stimulated, additional testosterone may not further fuel cancer growth. While not applicable to men with active or advanced disease, this research has opened doors for survivors struggling with fatigue, cognitive decline, and sexual dysfunction after curative therapy.

Dr. Van Hoof also highlights emerging PSMA-targeted theranostics as another frontier reshaping prostate cancer care. Initially developed as imaging tracers for PET scans, PSMA-based ligands are now being paired with therapeutic agents, allowing clinicians to both visualize and treat metastatic disease with unprecedented specificity. These approaches represent a convergence of diagnostics and therapeutics that aligns with precision oncology’s broader goals.

What unites these advances, Dr. Van Hoof suggests, is a growing respect for individualized decision-making. Prostate cancer is no longer treated as a monolithic disease but as a spectrum of biologically distinct conditions requiring tailored strategies. The challenge for clinicians is not simply choosing the most powerful therapy, but selecting the right therapy for the right patient at the right time.

In this evolving landscape, education plays a critical role. As Dr. Van Hoof’s insights reveal, today’s “standard of care” is increasingly defined not by rigid protocols, but by adaptive frameworks that integrate biology, imaging, genetics, and patient priorities. Prostate cancer care, once dominated by suppression alone, is now entering an era defined by balance, precision, and informed restraint.

FROM THE SOURCE

Alexander Van Hoof, MD, is a clinical researcher in urology with a focused expertise in prostate cancer, bladder cancer, and renal cancer. With more than a decade of experience in medical and clinical trial research, his work spans urologic oncology, evidence generation, and translational science. Through extensive academic involvement—including scientific writing, abstracts, and publications—Dr. Van Hoof has developed strong proficiency in interpreting complex medical data and effectively disseminating it to diverse clinical audiences. He has presented research findings to physicians and key opinion leaders at national medical conferences, earning recognition for clarity and impact. His clinical training as a medical doctor, combined with hands-on experience in clinical trials, has provided firsthand insight into how cutting-edge research and emerging technologies meaningfully affect patients and their families. Dr. Van Hoof is particularly passionate about leveraging his expertise in medical affairs and alues interdisciplinary collaboration, mentorship, and lifelong learning as essential drivers of progress in modern cancer care.

 

---

Part 2:

Imaging as the Unifying Force across Standard Therapies

By Robert L. Bard, MD, DABR, FAIUM, FASLMS
Cancer Radiologist | Diagnostic Imaging Specialist

Prostate cancer care has evolved into a highly structured, evidence-based continuum—one that balances disease biology, patient risk stratification, and quality-of-life considerations. Across decades of clinical observation and imaging-based assessment, it is clear that no single therapy stands alone. Instead, modern prostate cancer management is defined by appropriate treatment selection, timely intervention, and objective monitoring, all anchored by diagnostic imaging.

As a cancer radiologist specializing in advanced diagnostic imaging, my role is not to replace standard therapies, but to corroborate, validate, and refine them. Imaging serves as the common language that links surveillance, intervention, and follow-up—ensuring that treatment decisions align with tumor behavior rather than assumptions alone.

---

Risk Stratification and the Foundation of Care

Current standards of prostate cancer treatment appropriately rely on risk group classification, clinical staging, PSA kinetics, Gleason grading, and overall patient health. These variables determine whether a patient is best served by conservative monitoring or active intervention.

Imaging has become indispensable in this process. High-resolution ultrasound, multiparametric MRI, PET-based tracers, and Doppler vascular assessment now provide real-time insights into tumor location, aggressiveness, vascularity, and response to therapy—allowing clinicians to act with precision rather than excess.

---

Primary Treatments (Localized / Curative Intent)

Active Surveillance and Watchful Waiting: For patients with low-risk, slow-growing prostate cancer, active surveillance remains a clinically sound and patient-centered strategy. Imaging plays a critical role in this pathway by confirming disease stability, detecting subtle progression, and reducing unnecessary biopsies or premature treatment. Surveillance is not passive—it is data-driven vigilance.

Surgery: Radical Prostatectomy- Radical prostatectomy remains a cornerstone curative option, particularly for localized disease in otherwise healthy patients. Preoperative imaging assists in surgical planning, margin assessment, and lymph node evaluation, while postoperative imaging helps identify recurrence early, should PSA levels rise.

 

Radiation Therapy- has advanced significantly, offering multiple precise modalities:

• External Beam Radiation Therapy (EBRT)
• Intensity-Modulated Radiation Therapy (IMRT)
• Brachytherapy (radioactive seed implantation)

In addition, proton therapy and CyberKnife® stereotactic radiosurgery represent highly refined radiation approaches. Proton therapy allows for targeted dose delivery with reduced collateral tissue exposure, while CyberKnife uses robotic X-ray guidance for sub-millimeter accuracy. Imaging is essential in treatment planning, targeting, and post-therapy assessment for all radiation modalities.

---

Advanced or Recurrent Disease Treatments

Hormone Therapy (Androgen Deprivation Therapy – ADT)

Hormone therapy remains foundational in advanced, recurrent, or metastatic prostate cancer. Agents such as Lupron®, Firmagon®, and Orgovyx® suppress testosterone signaling to slow disease progression. Imaging helps determine treatment response, detect castration-resistant changes, and guide escalation or combination strategies.

Chemotherapy: Systemic agents such as docetaxel and cabazitaxel are used when prostate cancer spreads or becomes resistant to hormone therapy. Imaging evaluates disease burden, tracks metastatic spread, and informs timing and effectiveness of chemotherapy interventions.

Targeted Therapy: The emergence of genetically targeted therapies, including PARP inhibitors like olaparib, has introduced a new level of personalization. Imaging complements genomic testing by demonstrating phenotypic response and guiding treatment continuation or adjustment.

Immunotherapy: Immunotherapeutic approaches such as Sipuleucel-T represent an important option for select patients. While immune response may not always be immediately reflected in PSA changes, imaging provides objective insight into disease stabilization or progression.

Radiopharmaceutical Therapy: Radium-223 is a targeted radiopharmaceutical used specifically for prostate cancer metastases to bone. Imaging is critical in identifying appropriate candidates, monitoring skeletal response, and distinguishing therapeutic benefit from disease-related bone changes.

 

---

Ablative and Supportive Treatment Modalities

Cryotherapy and HIFU: Minimally invasive ablative techniques such as cryotherapy and high-intensity focused ultrasound (HIFU) are increasingly utilized in focal therapy or salvage settings. Imaging ensures accurate targeting, confirms tissue ablation, and monitors adjacent structures.

Bone-Targeted Therapy: For patients with bone metastases, bisphosphonates and denosumab are essential for skeletal protection and pain management. Imaging tracks bone integrity, fracture risk, and therapeutic response.

 

---

Imaging as the Integrator of Prostate Cancer Care

Across all treatment categories—whether curative, systemic, or palliative—diagnostic imaging serves as the objective validator. It informs when to treat, how aggressively to intervene, and when to adjust course. Imaging transforms prostate cancer care from protocol-driven to precision-guided, reducing overtreatment while safeguarding against missed progression.

The future of prostate cancer management lies not in choosing one therapy over another, but in intelligent integration—where surgery, radiation, hormone therapy, systemic agents, and emerging technologies are applied in harmony, guided by accurate, real-time diagnostic insight.

---

Closing Perspective

Modern prostate cancer care is robust, multidisciplinary, and continually advancing. Current standards—from active surveillance to proton therapy, CyberKnife, systemic treatments, and supportive care—are well-founded and effective when applied appropriately. Diagnostic imaging stands at the center of this ecosystem, ensuring that every decision is informed, justified, and aligned with the patient’s unique disease profile.

In prostate cancer, seeing clearly is not optional—it is essential.